Journal Article > ResearchFull Text
PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali MA, et al.
PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.